Annovis Bio Inc. (ANVS) Closes $21M Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Annovis Bio, Inc. Announces Closing of $21 Million Public Offering
February 4, 2025 4:31 PM ESTMALVERN, PA, Feb. 04, 2025 (GLOBE NEWSWIRE) -- via IBN -Â Annovis Bio, Inc. (NYSE: ANVS) (Annovis or the Company), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimers disease (AD) and Parkinsons disease (PD), today announced the closing of its previously announced underwritten public offering of 5,250,000 shares of common stock and warrants to purchase 5,250,000 shares of common stock at a combined public offering price of $4.00 per share and associated warrant. The warrants have an exercise price of $5.00 per share and are immediately exercisable upon issuance... More
